SGLT2 inhibitor administration was associated with a reduced risk of all-cause death (RR 0.88; 95% CI: 0.83–0.94; p for heterogeneity 0.09; I2 = 44%; p < 0.01) (Figure 5), MACEs (random model RR 0.88; 95% CI: 0.81–0.95; p for heterogeneity 0.07; I2 = 51%; p < 0.01) (Figure 5), CV death (RR 0.86; 95% CI: 0.79–0.93; p for heterogeneity 0.14; I2 = 35%; p < 0.01) (Figure 5), and HF hospitalization (RR 0.70; 95% CI: 0.65–0.75; p for heterogeneity 0.79; I2 = 0%; p < 0.01) (Figure 5) in diabetic patients compared to placebo. This evidence concerns the gene SLC5A2 and hydrops fetalis.